- Home
- AKBA vs RNTZ Comparison
AKBA vs RNTZ Comparison
Compare AKBA & RNTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AKBA | RNTZ |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Water Sewer Pipeline Comm & Power Line Construction |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.3M | 271.0M |
| IPO Year | 2014 | 2023 |
Fundamental Metrics
Financial Performance| Metric | AKBA | RNTZ |
|---|---|---|
| Price | $0.57 | $4.94 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $3.25 | N/A |
| AVG Volume (30 Days) | ★ 9.5M | 10.6K |
| Earning Date | 11-05-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 93.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $3.57 |
| 52 Week High | $1.84 | $5.18 |
Technical Indicators
Market Signals| Indicator | AKBA | RNTZ |
|---|---|---|
| Relative Strength Index (RSI) | 41.52 | 61.50 |
| Support Level | $0.54 | $3.96 |
| Resistance Level | $1.00 | $5.18 |
| Average True Range (ATR) | 0.07 | 0.54 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 45.81 | 70.98 |
Price Performance
Historical ComparisonAbout AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.